Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 29.04.2024 3 Am J Surg 1 Am J Surg Pathol 1 Ann Oncol 1 Ann Surg Oncol 1 BMC Cancer 1 Br J Cancer 11 Breast Cancer 6 Breast Cancer Res 9 Breast Cancer Res Treat 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Surg Oncol 1 Eur Radiol 2 Histopathology 1 J Biol Chem 1 J Clin Oncol 1 J Nucl Med 3 J Surg Oncol 2 JAMA 1 Mod Pathol 1 N Engl J Med 3 NPJ Breast Cancer 1 Proc Natl Acad Sci U S A 2 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. MOUSA-DOUST D, Warburton R, Pao JS, Dingee C, et al
   Paget's disease of the breast: Presentation, treatment, and outcomes in a modern cohort.
   Am J Surg. 2024;231:18-23.
   PubMed         Abstract available
   
   
2. DALTON JC, Plichta JK
   Paget's disease of the breast: Insights from imaging to guide surgical management.
   Am J Surg. 2024;231:16-17.
   PubMed        
   
   
3. TANG K, Sutherland JM, Liu G, Crump T, et al
   Preoperative depression and anxiety associated with younger age and receipt of immediate breast reconstruction.
   Am J Surg. 2024;231:106-112.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

4. LENNARTZ M, Lohr N, Hoflmayer D, Dwertmann Rico S, et al
   TRPS1 is a Highly Sensitive Marker for Breast Cancer: A Tissue Microarray Study Evaluating More Than 19,000 Tumors From 152 Different Tumor Entities.
   Am J Surg Pathol. 2024 Apr 22. doi: 10.1097/PAS.0000000000002213.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. PETERS S, Loi S, Andre F, Chandarlapaty S, et al
   Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
   Ann Oncol. 2024 Apr 20:S0923-7534(24)00108-X. doi: 10.1016/j.annonc.2024.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. ROACH EA, Weil CR, Cannon G, Grant J, et al
   The Role of Axillary Lymph Node Dissection versus Sentinel Lymph Node Dissection in Breast Cancer Patients with Clinical N2b-N3c Disease Who Receive Adjuvant Radiotherapy.
   Ann Surg Oncol. 2024 Apr 22. doi: 10.1245/s10434-024-15280.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. ZOU J, Chen Q, He Y, Pan Y, et al
   Systematic optimization and evaluation of culture conditions for the construction of circulating tumor cell clusters using breast cancer cell lines.
   BMC Cancer. 2024;24:507.
   PubMed         Abstract available
   
   

   
   Br J Cancer

8. HANNA D, Merrick S, Ghose A, Devlin MJ, et al
   Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
   Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685.
   PubMed         Abstract available
   
   

   
   Breast Cancer

9. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
   Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
   Breast Cancer. 2024;31:536-538.
   PubMed        
   
   
10. YANG PJ, Tsai EM, Hou MF, Lee YJ, et al
    Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors.
    Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01579.
    PubMed         Abstract available
    
    
11. YOSHINAMI T
    Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy.
    Breast Cancer. 2024 Apr 23. doi: 10.1007/s12282-024-01571.
    PubMed         Abstract available
    
    
12. ALTUNDAG K
    Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients.
    Breast Cancer. 2024 Apr 22. doi: 10.1007/s12282-024-01587.
    PubMed        
    
    
13. SHANG Y, Wang X, Liu Y, Cheng W, et al
    Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
    Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01583.
    PubMed         Abstract available
    
    
14. NA S, Kim M, Park Y, Kwon HJ, et al
    Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.
    Breast Cancer. 2024 Apr 21. doi: 10.1007/s12282-024-01585.
    PubMed         Abstract available
    
    
15. YOSHINAMI T, Nagai SE, Hattori M, Okamura T, et al
    Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or seco
    Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575.
    PubMed         Abstract available
    
    
16. VAN ROOIJ JAF, Bijkerk E, van der Hulst RRJW, Tuinder SMH, et al
    The influence of a previous implant-based breast reconstruction on postoperative sensation of the deep inferior epigastric artery perforator flap.
    Breast Cancer. 2024;31:456-466.
    PubMed         Abstract available
    
    
17. NOGI H, Ogiya A, Ishitobi M, Yamauchi C, et al
    Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
    Breast Cancer. 2024;31:507-518.
    PubMed         Abstract available
    
    
18. TSUCHIDA Y, Niikura N, Chishima T, Mizuno M, et al
    Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX(R) test data: a retrospective multicenter study in Japan.
    Breast Cancer. 2024;31:401-408.
    PubMed         Abstract available
    
    
19. CH'NG ES
    Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.
    Breast Cancer. 2024;31:496-506.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

20. KWON MR, Chang Y, Ham SY, Cho Y, et al
    Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection.
    Breast Cancer Res. 2024;26:68.
    PubMed         Abstract available
    
    
21. PAN JW, Ragu M, Chan WQ, Hasan SN, et al
    Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
    Breast Cancer Res. 2024;26:67.
    PubMed         Abstract available
    
    
22. JACOBS SA, Wang Y, Abraham J, Feng H, et al
    NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:69.
    PubMed         Abstract available
    
    
23. LIAO R, Chen X, Cao Q, Bai L, et al
    AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.
    Breast Cancer Res. 2024;26:70.
    PubMed         Abstract available
    
    
24. HE L, Qin Y, Hu Q, Liu Z, et al
    Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging.
    Breast Cancer Res. 2024;26:71.
    PubMed         Abstract available
    
    
25. CHAUDHARY P, Yadav K, Lee HJ, Kang KW, et al
    siRNA treatment targeting integrin alpha11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
    Breast Cancer Res. 2024;26:72.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

26. YADAV SK, Bharath S, Sharma D, Srivastava A, et al
    A systematic review and meta-analysis of diagnostic performance of fluorescein-guided sentinel lymph node biopsy in early breast cancer.
    Breast Cancer Res Treat. 2024 Apr 26. doi: 10.1007/s10549-024-07310.
    PubMed         Abstract available
    
    
27. BRADBURY M, Savard MF, Stober C, Clemons L, et al
    Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.
    Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302.
    PubMed         Abstract available
    
    
28. LEE SY, Yoo TK, Kim J, Chung IY, et al
    Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer.
    Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07305.
    PubMed         Abstract available
    
    
29. SHI Y, Lu H, Zhang Y
    Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 Apr 24. doi: 10.1007/s10549-024-07317.
    PubMed         Abstract available
    
    
30. CHLEBOWSKI RT, Aragaki AK, Pan K, Mortimer JE, et al
    Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
    Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07307.
    PubMed         Abstract available
    
    
31. BERTELSEN BE, Almas B, Fjermeros K, Viste K, et al
    Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
    Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07313.
    PubMed         Abstract available
    
    
32. LEONARD S, Jones AN, Newman L, Chavez-MacGregor M, et al
    Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.
    Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308.
    PubMed         Abstract available
    
    
33. DA SILVA JL, de Albuquerque LZ, Rodrigues MES, Thuler LCS, et al
    Ethnic disparities in breast cancer patterns in Brazil: examining findings from population-based registries.
    Breast Cancer Res Treat. 2024 Apr 21. doi: 10.1007/s10549-024-07314.
    PubMed         Abstract available
    
    
34. HSU R, Al-Zubeidy B, Flores D, Nazarian A, et al
    Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer.
    Breast Cancer Res Treat. 2024 Apr 20. doi: 10.1007/s10549-024-07295.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

35. PARADA H, Wu T, Hoh E, Rock CL, et al
    Red Blood Cell Polyunsaturated Fatty Acids and Mortality Following Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed         Abstract available
    
    

    
    Cancer Res

36. XIA J, Zhang L, Peng X, Tu J, et al
    IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer.
    Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3429.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

37. KONG CY, Williams J, Hemadasa N, Murphy D, et al
    The Introduction of Magtrace(R) Lymphatic Tracer for Axillary Sentinel Node Biopsy for Breast Cancer in a Rural Scottish District General Hospital: Initial Experience, Perspectives, Outcomes and Learning Curves.
    Clin Breast Cancer. 2024 Mar 30:S1526-8209(24)00099.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

38. BOTTOSSO M, Miglietta F, Vernaci GM, Giarratano T, et al
    Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer.
    Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

39. OGIYA A, Kimura K, Ueno T, Iwase T, et al
    Time trend of breast cancer-related lymphedema according to body mass index.
    Eur J Surg Oncol. 2024;50:108350.
    PubMed         Abstract available
    
    

    
    Eur Radiol

40. MARCON M, Fuchsjager MH, Clauser P, Mann RM, et al
    ESR Essentials: screening for breast cancer - general recommendations by EUSOBI.
    Eur Radiol. 2024 Apr 24. doi: 10.1007/s00330-024-10740.
    PubMed         Abstract available
    
    

    
    Histopathology

41. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    PubMed         Abstract available
    
    
42. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    PubMed         Abstract available
    
    

    
    J Biol Chem

43. YANG P, Li Y, Hou J, Wu D, et al
    Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.
    J Biol Chem. 2024 Apr 22:107309. doi: 10.1016/j.jbc.2024.107309.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

44. BARDIA A, Krop IE, Kogawa T, Juric D, et al
    Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
    J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909.
    PubMed         Abstract available
    
    

    
    J Nucl Med

45. ZHOU W, Halder S, Herwald S, Ghijsen M, et al
    Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas.
    J Nucl Med. 2024 Apr 25:jnumed.123.266659. doi: 10.2967/jnumed.123.266659.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

46. SPIEKERMAN VAN WEEZELENBURG MA, Daemen JHT, van Kuijk SMJ, van Haaren ERM, et al
    Seroma formation after mastectomy: A systematic review and network meta-analysis of different flap fixation techniques.
    J Surg Oncol. 2024;129:1015-1024.
    PubMed         Abstract available
    
    
47. KEATING N, Cevik J, Hopkins D, Lippey J, et al
    Malignant upgrade rate and associated clinicopathologic predictors for concordant intraductal papilloma without atypia: A systematic review and meta-analysis.
    J Surg Oncol. 2024;129:1025-1033.
    PubMed         Abstract available
    
    
48. ABAHSSAIN H, Souadka A
    Navigating the complexity of post-NAT therapy in breast cancer: The role of ctDNA testing.
    J Surg Oncol. 2024 Apr 23. doi: 10.1002/jso.27658.
    PubMed        
    
    

    
    JAMA

49. JATOI I
    US Breast Cancer Mortality.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5479.
    PubMed        
    
    
50. CASWELL-JIN JL, Kurian AW, Plevritis SK
    US Breast Cancer Mortality-Reply.
    JAMA. 2024 Apr 25. doi: 10.1001/jama.2024.5482.
    PubMed        
    
    

    
    Mod Pathol

51. HARINATH L, Villatoro TM, Clark BZ, Fine JL, et al
    Upgrade Rates of Variant Lobular Carcinoma In Situ Compared to Classic Lobular Carcinoma In Situ Diagnosed in Core Needle Biopsies: A 10-Year Single Institution Retrospective Study.
    Mod Pathol. 2024;37:100462.
    PubMed         Abstract available
    
    

    
    N Engl J Med

52. MCGUIRE KP
    Axillary Dissection - The Bell Tolls for Thee.
    N Engl J Med. 2024;390:1231-1232.
    PubMed        
    
    

    
    NPJ Breast Cancer

53. CHAUHAN SK, Dunn C, Andresen NK, Rossevold AH, et al
    Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation.
    NPJ Breast Cancer. 2024;10:30.
    PubMed         Abstract available
    
    
54. VEERLA S, Staaf J
    Kataegis in clinical and molecular subgroups of primary breast cancer.
    NPJ Breast Cancer. 2024;10:32.
    PubMed         Abstract available
    
    
55. HURVITZ SA, Bardia A, Punie K, Kalinsky K, et al
    Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:33.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

56. MONDAL DK, Xie C, Pascal GJ, Buraschi S, et al
    Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progression.
    Proc Natl Acad Sci U S A. 2024;121:e2317760121.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

57. HANNOUN-LEVI JM, Gimeno Morales M, Gal J, Anchuelo J, et al
    Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort.
    Radiother Oncol. 2024;194:110217.
    PubMed         Abstract available
    
    
58. CICCHETTI A, Mangili P, Fodor A, Gabellini MGU, et al
    Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy.
    Radiother Oncol. 2024;194:110183.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.